Home / Market News / $ADAG
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Adagene and City of Hope Launch Phase 1 Clinical Trial for Metastatic Colorectal Cancer Combination Therapy

Nov 18, 2026, 1:03 AM UTC · Primary ticker $ADAG

Adagene and City of Hope have initiated a Phase 1 clinical trial for a novel combination therapy targeting metastatic colorectal cancer. This development is a positive step for Adagene, showcasing progress in its drug pipeline and potentially opening new treatment avenues for a difficult-to-treat cancer.

Adagene Inc. and City of Hope announced the launch of a Phase 1 clinical trial for a combination therapy involving ivonescimab, Adagene's muzastotug (ADG126), and chemotherapy for metastatic colorectal cancer. This is a significant step for Adagene as it moves its proprietary SAFEbody technology further into clinical development, validating its platform. For traders, this represents a long-term opportunity if the trial shows promising results, as successful clinical trials can significantly boost a biotech company's valuation. The short-term impact might be moderate as it's only a Phase 1 trial, but it de-risks the drug to some extent. The key risk is that Phase 1 trials are primarily for safety, and efficacy data will be crucial for future phases.

$ADAG positive Advancement of pipeline drug into clinical trials
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.